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“arbitrary assumptions on model parameters like the of follow-up. From one 10-year-old reference is the mes-
sage that “routine measurement of vitamin B12 concentra-glomerular transmembrane hydraulic pressure and the
tions and inclusion of vitamin B12 in the supplementsultrafiltration coefficient” is uncorrect since the theoreti-
should completely eliminate . . . the risk of masking vita-cal model depends only on one assumed parameter, the
min B12 deficiency.” Because close surveillance is sug-glomerular transmembrane pressure. Assuming this pa-
gested to look for adverse effects produced from folaterameter, the value of the ultrafiltration coefficient is con-
fortification of food in the general population, which in-sequently derived. In addition, we and others have shown
creases serum folate from 10.8 to 19.0 ng/mL [2], how canthat the influence of the glomerular transmembrane pres-
we forecast that in uremic people values as high as 200sure on the calculated shunt parameter omega is negligi-
to 400 ng/mL are safe over a long time? Treatment forble [5, 6]. Thus, the criticism that no unique model can
hyperhomocysteinemia in uremic patients results in nor-be identified is not appropriate.
mal vitamin B12 coupled with very high folate concen-
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Monitoring side effects in thousands of patients receiv-
To the Editor: The excellent paper by De Vriese et al ing 0.4 to 4,0 mg folate and in smaller numbers taking
in a recent issue of Kidney International on folate for large doses for several years has revealed no evidence for
cardiovascular disease in uremia largely underestimates toxicity [1, 2]. In renal failure patients, no side effects
the risk of folate overdose [1]. The suggestion that “high have been reported so far, the longest follow-up being 17
doses of folic acid are well tolerated and safe” takes root months.
Concerns about large-scale folate administration gener-from four studies with 4 to 8 weeks and 12 to 17 months
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Fig. 1. Distribution of serum folate (A) (nor-
mal value less than 20 ng/mL) and vitamin B12
(B) (300 to 2000 pg/mL) concentrations in our
148 patients on chronic dialysis after 6-month
continuous folate (15 mg/week) and vitamin B12
(1000 g/week) supplementation. Shaded areas
indicate normal ranges. The treatment-induced
unbalance between the two vitamins is clearly
shown. No patients have serum folate values
within the normal range, while more than 50%
of patients have serum folate values 5 to 15
times higher than the upper limits of safety.
On the contrary, 100% of patients have serum
vitamin B12 values within the normal range.
ally focus on its potential risks in cobalamin deficiency. unclear whether they were related to folate itself or to
other components of the formulation [1]. Although smallFolate does not lower cobalamin levels and no strong evi-
dence supports the allegation that folate exacerbates the non-controlled studies suggested that folate reduced zinc
absorption, subsequent larger randomized studies foundneurologic manifestations of cobalamin deficiency [1].
However, folate reverses the typical hematologic abnor- no interference with zinc homeostasis [1].
The concerns about neurotoxicity are based on animalmalities of the disorder and may thus compromise its
diagnosis. Patients with renal failure should therefore studies and one report of seizures in a patient with poorly
controlled epilepsy after high intravenous doses [5]. Neph-receive folate along with vitamin B12, after exclusion of
cobalamin deficiency [3]. Food fortification with folate is rotoxicity was observed in developing rats receiving meg-
adoses of folate [6]. No reports of renal damage in humansa quite different situation, as it affects the general popula-
tion and systematic surveillance of cobalamin levels is have been found.
As stated in an excellent review on folate safety, “theimpossible [4].
A carcinogenic effect of folate has been suggested, but data that suggest that folate supplements are unsafe are
weak and consist predominantly of case series and re-not confirmed in subsequent studies. Rather, a protective
effect regarding several malignancies has been found [1]. ports” [1]. Although there is little evidence that folate
causes important side effects at doses recommended inHypersensitivity reactions have been reported, but it was
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